Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)

被引:27
|
作者
Palte, Rachel L. [1 ]
Schneider, Sebastian E. [1 ]
Altman, Michael D. [1 ]
Hayes, Robert P. [2 ]
Kawamura, Shuhei [1 ]
Lacey, Brian M. [1 ]
Mansueto, My Sam [1 ]
Reutershan, Michael [1 ]
Siliphaivanh, Phieng [1 ]
Sondey, Christopher [1 ]
Xu, Haiyan [1 ]
Xu, Zangwei [1 ]
Ye, Yingchun [1 ]
Machacek, Michelle R. [1 ]
机构
[1] Merck & Co Inc, Computat & Struct Chem, Boston, MA 02115 USA
[2] Computat & Struct Chem, West Point, PA 19486 USA
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 09期
关键词
PRMT5; allosteric inhibition; methyltransferase; peptide competitive; SAM competitive; crystal structure; SELECTIVE INHIBITOR; METHYLATION; POTENT; DISCOVERY; DELETION; HISTONE;
D O I
10.1021/acsmedchemlett.9b00525
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein arginine methyltransferase 5 (PRMT5) belongs to a family of enzymes that regulate the posttranslational modification of histones and other proteins via methylation of arginine. Methylation of histones is linked to an increase in transcription and regulates a manifold of functions such as signal transduction and transcriptional regulation. PRMT5 has been shown to be upregulated in the tumor environment of several cancer types, and the inhibition of PRMT5 activity was identified as a potential way to reduce tumor growth. Previously, four different modes of PRMT5 inhibition were known-competing (covalently or non-covalently) with the essential cofactor Sadenosyl methionine (SAM), blocking the substrate binding pocket, or blocking both simultaneously. Herein we describe an unprecedented conformation of PRMT5 in which the formation of an allosteric binding pocket abrogates the enzyme's canonical binding site and present the discovery of potent small molecule allosteric PRMT5 inhibitors.
引用
收藏
页码:1688 / 1693
页数:6
相关论文
共 50 条
  • [41] In silico analysis of marine natural product for protein arginine methyltransferase 5(PRMT5) inhibitors based on pharmacophore and molecular docking
    Luo, Lianxiang
    Tan, Huiting
    Liao, Yinglin
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (22): : 13180 - 13197
  • [42] LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity
    Bonday, Zahid Q.
    Cortez, Guillermo S.
    Grogan, Michael J.
    Antonysamy, Stephen
    Weichert, Ken
    Bocchinfuso, Wayne P.
    Li, Fengling
    Kennedy, Steven
    Li, Binghui
    Mader, Mary M.
    Arrowsmith, Cheryl H.
    Brown, Peter J.
    Eram, Mohammad S.
    Szewczyk, Magdalena M.
    Barsyte-Lovejoy, Dalia
    Vedadi, Masoud
    Guccione, Ernesto
    Campbell, Robert M.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (07): : 612 - 617
  • [43] Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the canine model of non-Hodgkin lymphoma
    Renaldo, Kyle A.
    Courtney, Lindsay E.
    Shilo, Konstantin
    Baiocchi, Robert A.
    Kisseberth, William C.
    CANCER RESEARCH, 2018, 78 (13)
  • [44] MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
    Kryukov, Gregory V.
    Wilson, Frederick H.
    Ruth, Jason R.
    Paulk, Joshiawa
    Tsherniak, Aviad
    Marlow, Sara E.
    Vazquez, Francisca
    Weir, Barbara A.
    Fitzgerald, Mark E.
    Tanaka, Minoru
    Bielski, Craig M.
    Scott, Justin M.
    Dennis, Courtney
    Cowley, Glenn S.
    Boehm, Jesse S.
    Root, David E.
    Golub, Todd R.
    Clish, Clary B.
    Bradner, James E.
    Hahn, William C.
    Garraway, Levi A.
    SCIENCE, 2016, 351 (6278) : 1214 - 1218
  • [45] Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies
    Zheng, Jiahong
    Li, Bang
    Wu, Yingqi
    Wu, Xiaoshuang
    Wang, Yuanxiang
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (13) : 8407 - 8427
  • [46] The arginine methyltransferase PRMT5 regulates CIITA-dependent MHC II transcription
    Fan, Zhiwen
    Kong, Xiaocen
    Xia, Jun
    Wu, Xiaoyan
    Li, He
    Xu, Huihui
    Fang, Mingming
    Xu, Yong
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2016, 1859 (05): : 687 - 696
  • [47] The protein arginine methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-dependent chromatin remodeling
    Dacwag, Caroline S.
    Ohkawa, Yasuyuki
    Pal, Sharmistha
    Sif, Said
    Imbalzano, Anthony N.
    MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (01) : 384 - 394
  • [48] Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
    Vlummens, Philip
    Verhulst, Stefaan
    De Veirman, Kim
    Maes, Anke
    Menu, Eline
    Moreaux, Jerome
    De Boussac, Hugues
    Robert, Nicolas
    De Bruyne, Elke
    Hose, Dirk
    Offner, Fritz
    Vanderkerken, Karin
    Maes, Ken
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [49] PRMT5, which forms distinct homo-oligomers, is a member of the protein-arginine methyltransferase family
    Rho, J
    Choi, S
    Seong, YR
    Cho, WK
    Kim, SH
    Im, DS
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) : 11393 - 11401
  • [50] Protein Arginine Methyltransferase 5 (PRMT5) Signaling Suppresses Protein Kinase Cδ- and p38δ-dependent Signaling and Keratinocyte Differentiation
    Kanade, Santosh R.
    Eckert, Richard L.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (10) : 7313 - 7323